Printer Friendly

AFFINITY BIOTECH APPOINTS NEW CHIEF FINANCIAL OFFICER

 BOOTHWYN, Pa., Sept. 13 /PRNewswire/ -- Affinity Biotech, Inc. (NASDAQ: AFBI) today announced that is has appointed Dennis M. Foss, 52, as its chief financial officer and treasurer. Mr. Foss replaces Joseph L. Jackson, 66, who remains secretary of the company and a member of its board of directors. Mr. Foss, who assumed his new positions Aug. 1, 1993, will oversee Affinity's non-research and development administrative functions in addition to his financial management responsibilities.
 Mr. Foss brings his broad financial and management experience to Affinity following a highly successful 10-year tenure with closely held Shelter Systems Group Corporation, a Hainesport, N.J., the largest housing component manufacturer in the United States. Mr. Foss served as Shelter Systems' executive vice president for the past seven years and as its chief financial officer for the past 10 years. During the past three years, he also served as president of one of its operating divisions. In addition to his financial and operations responsibilities, while at Shelter Systems Mr. Foss focused on mergers and acquisitions.
 Mr. Foss is a certified public accountant with a B.S. from California State University at Sacramento. Before joining Shelter Systems, Mr. Foss was employed by Campbell Soup Company and Price Waterhouse & Co. "Affinity will benefit greatly from the addition of Dennis Foss to our team," said Wayne Weisman, executive vice president of Affinity. "His considerable financial skills will be crucial as we expand our business development activities."
 Joseph L. Jackson, who has been Affinity's chief financial officer since the company's inception in 1990, is retiring from that position but will remain actively involved with the company. "The employees and directors of Affinity thank Joe Jackson for the exceptional effort he has made on the company's behalf since its inception in 1990," said Alan Dickason, Affinity's president and CEO. "Although he is retiring as chief financial officer, we look forward to his continuing valuable contributions as our secretary and as member of Affinity's board of directors."
 Based in Boothwyn, Affinity Biotech focuses on the development of oral drug delivery systems for proteins, peptides and other therapeutic agents, the formulation of taste masked liquids and chewable drugs, and the development of other pharmaceutical products utilizing Affinity's expertise in surface chemistry.
 -0- 9/13/93
 /CONTACT: Wayne B. Weisman, executive vice president of Affinity Biotech, Inc., 215-497-0500, or Anthony J. Russo, Ph.D., of Noonan/Russo Communications, 212-979-9180/
 (AFBI)


CO: Affinity Biotech, Inc. ST: Pennsylvania IN: MTC SU: PER

SH-TS -- NY013 -- 1111 09/13/93 08:37 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 13, 1993
Words:416
Previous Article:SPECTRUM AND MOTOROLA IN AGREEMENT FOR DEVELOPMENT AND SUPPLY OF DSP BOARDS THROUGH 1994
Next Article:SONOCO PRODUCTS TO SIGNIFICANTLY EXPAND CONSUMER PACKAGING BUSINESS; WILL OFFER $15.63 PER SHARE FOR ALL ENGRAPH STOCK
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters